Key Highlights
- Charles River and Lundbeck partner to leverage the AI-powered Logica® platform for neurological research.
- Logica integrates AI and advanced tools for drug discovery, enhancing the development of novel therapies.
- Lundbeck aims to create optimized small molecules targeting neurodegenerative diseases.
Source: Business Wire
Notable Quotes
- “We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease.” — Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer at Charles River
- “Partnering with Logica will allow us to use a unique tool set, including AI-driven approaches, to overcome drug design challenges.” – Tarek Samad, Senior Vice President and Head of Global Research at Lundbeck
SoHC's Take
This collaboration between Charles River and Lundbeck represents a significant step forward in addressing the complexities of neurodegenerative diseases. By combining Lundbeck’s expertise in neurology with the AI-driven capabilities of Logica, the partnership is poised to accelerate drug discovery, potentially bringing novel therapies to patients faster. This innovative approach not only enhances the precision of preclinical candidate development but also positions both companies as leaders in AI-powered drug research.
